There's one big difference though - Pfizer is seeking a green light for second booster dose ... or approved COVID-19 vaccines. Unlike Pfizer, Moderna did not highlight any new data to support ...

Moderna has ... version of its COVID-19 vaccine that combines its original version with another targeting the Beta variant, and seems to offer improved protection. The booster shot – called ...

A protein-based booster vaccine made by Novavax, which works differently to the Pfizer and Moderna jabs, is also available. Moderna hopes to launch a combined flu and Covid vaccine later in 2025 ...

Starting from April 8, people aged 65 and older, indigenous people aged 55 to 64, children younger than six months old and people who are immunocompromised would be eligible for a booster shot ... Six ...

New research findings provide solid evidence that annual COVID-19 vaccine booster doses continue to be advisable for certain immunocompromised people, researchers at McGill University say. The ...

New research findings provide solid evidence that annual COVID-19 vaccine booster doses continue to be advisable for certain immunocompromised people, researchers at McGill University say.

The NHS Covid spring booster campaign is under way ... firm selects Oxfordshire as the site for a new UK research and production base. Moderna said it is suing Pfizer and its German partner ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of ...

Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For 2025, Moderna forecasts total company sales of between $1.5 billion and $2.5 ...

New research from McGill University has found that some immunocompromised people should still receive annual COVID-19 vaccine boosters.